Therapeutics, drug discovery, and the platforms behind them — private biotech ranked by valuation.
| # | Company | Valuation | Secondary $/sh | vs Last Round | Last Round | IPO Status |
|---|---|---|---|---|---|---|
| 1 | Colossal Biosciences Dallas, Texas |
$30Bmark 2026-07 | $8.50as of 2026-06-27 | -65.8% | Series C extension · 2025-09-17 · $120M | Private |
| 2 | Neuralink Fremont, California |
$15Bmark 2025-Q2 | no secondary mark | — | Series E · 2025-06-01 · $650M | none |
| 3 | Biosplice Therapeutics San Diego, CA |
$12Bmark 2018-Q3 | no secondary mark | — | Series E · 2018-08-15 · $438M | no imminent plans |
| 4 | Isomorphic Labs London, UK |
$12Bmark 2026-Q2 | $61.50as of 2026-06-27 | no round comparison | Series B · 2026-05-12 · $2.1B | no imminent plans |
| 5 | Resilience Blue Ash, OH |
$9.4Bmark 2023-Q1 | no secondary mark | — | Series D · 2023-01-04 · $625M | no imminent plans |
| 6 | Ro New York, NY |
$7.0Bmark 2025 | no secondary mark | — | Series D · 2022-02-22 · $150M | rumored |
| 7 | Benchling San Francisco, USA |
$6.1Bmark 2021-Q4 | no secondary mark | — | Series F · 2021-11-18 · $100M | rumored |
| 8 | SandboxAQ Palo Alto, CA |
$5.1Bmark 2025-Q2 | $21.35as of 2026-06-27 | +24.1% | Series E · 2025-04-03 · $450M | Private |
| 9 | Color Burlingame, CA |
$4.6Bmark 2021-Q4 | $12.24as of 2026-06-27 | -87.8% | Series E · 2021-11-08 · $100M | private |
| 10 | Sword Health New York, NY |
$4.5Bmark 2025-Q2 | $27.83as of 2026-06-27 | -61.1% | Series F · 2025-06-17 · $40M | private |
| 11 | Chai Discovery San Francisco, CA |
$3.8Bmark 2026-07 | $47.97as of 2026-06-27 | -29.1% | Growth · 2026-07-14 · $400M | private |
| 12 | Ultima Genomics Fremont, CA |
$3.6Bmark 2022-Q2 | $24.96as of 2026-06-27 | -50.2% | Series E · 2022-05-31 · $229M | private |
| 13 | Judi Health New York, NY |
$3.3Bmark 2025-Q3 | $15.12as of 2026-06-27 | +12.1% | Series F · 2025-09-08 · $400M | private |
| 14 | Eat Just Alameda, CA |
$2.6Bmark 2022-Q3 | $4.27as of 2026-06-27 | no round comparison | Series F · 2022-08-17 · $25M | private |
| 15 | Insitro South San Francisco, CA |
$2.4Bmark 2021-Q1 | $12.94as of 2026-06-27 | -29.3% | Series C · 2021-03-19 · $400M | no imminent plans |
| 16 | Solugen Omaha, NE |
$2.2Bmark 2022-Q4 | $33.46as of 2026-06-27 | -17.8% | Series D · 2022-10-28 · $200M | private |
| 17 | Freenome Brisbane, CA |
$2.2Bmark 2024-Q1 | $1.48as of 2026-06-27 | -80.0% | Later Stage VC · 2024-02-14 · $254M | private |
| 18 | Medable Palo Alto, CA |
$2.1Bmark 2021-Q4 | $3.00as of 2026-06-27 | -69.0% | Series D · 2021-10-24 · $304M | private |
| 19 | ArsenalBio South San Francisco, CA |
$1.9Bmark 2024-Q3 | $15.59as of 2026-06-27 | -16.1% | Series C · 2024-09-04 · $325M | private |
| 20 | Formation Bio New York, NY |
$1.7Bmark 2024 | $2.61as of 2026-06-27 | -68.1% | undisclosed | private |
| 21 | Pivot Bio Berkeley, CA |
$1.7Bmark 2021-Q3 | $5.28as of 2026-06-27 | -30.4% | Series D · 2021-07-18 · $430M | private |
| 22 | Inari Cambridge, MA |
$1.6Bmark 2025-Q1 | $8.00as of 2026-06-27 | no round comparison | Later Stage VC · 2025-01-07 · $144M | private |
| 23 | SonderMind Greensboro, NC |
$1.6Bmark 2021-Q2 | $21.00as of 2026-06-27 | +16.5% | Series C · 2021-05-27 · $242M | private |
| 24 | NewLimit South San Francisco, CA |
$1.6Bmark 2025-Q4 | $21.47as of 2026-06-27 | no round comparison | Early Stage VC · 2025-10-19 · $45M | private |
| 25 | Science Alameda, CA |
$1.5Bmark 2026-Q1 | $4.76as of 2026-06-27 | no round comparison | Series C · 2026-03-05 · $230M | private |
| 26 | Valo Health Lexington, MA |
$1.4Bmark 2022-Q4 | no secondary mark | — | Series C · 2022-10-28 · $100M | private |
| 27 | RefleXion Medical Hayward, CA |
$1.3Bmark 2023-Q4 | no secondary mark | — | Series F · 2023-11-15 · $107M | private |
| 28 | Owkin Paris, France |
$1.3Bmark 2021-Q4 | $36.88as of 2026-06-27 | -14.3% | Series B · 2021-11-18 · $180M | private |
| 29 | BioIntellisense Golden, CO |
$1.2Bmark 2022-Q4 | no secondary mark | — | Early Stage VC · 2022-12-30 · $179M | private |
| 30 | Capsule New York, NY |
$1.2Bmark 2021-Q2 | no secondary mark | — | Series D · 2021-04-28 · $300M | private |
| 31 | Orca Bio Menlo Park, CA |
$1.2Bmark 2020-Q2 | $38.00as of 2026-06-27 | +8.5% | Series D · 2020-06-17 · $192M | private |
| 32 | Modern Health San Francisco, CA |
$1.2Bmark 2021-Q1 | $21.40as of 2026-06-27 | -51.4% | Series D · 2021-02-11 · $74M | private |
| 33 | Enveda Biosciences Boulder, CO |
$1.2Bmark 2025-Q3 | no secondary mark | — | Series D · 2025-09-04 · $150M | private |
| 34 | Kallyope New York, NY |
$1.1Bmark 2022-Q1 | no secondary mark | — | Series D · 2022-01-27 · $236M | private |
| 35 | Adimab Lebanon, NH |
$1.1Bmark 2015-Q1 | $57.00as of 2026-06-27 | no round comparison | Later Stage VC · 2015-01-31 · $100M | private |
| 36 | Thirty Madison New York, NY |
$1.0Bmark 2021-Q2 | $4.00as of 2026-06-27 | -79.2% | Series C · 2021-06-02 · $141M | private |
| 37 | Element Biosciences San Diego, CA |
$1.0Bmark 2024-Q3 | $4.00as of 2026-06-27 | -49.0% | Series D · 2024-07-10 · $277M | private |
| 38 | PathAI Boston, MA |
$1.0Bmark 2021-Q2 | $21.89as of 2026-06-27 | -25.8% | Series C · 2021-05-17 · $165M | private |
| 39 | Synchron Brooklyn, NY |
$1.0Bmark 2024-Q4 | $34.68as of 2026-06-27 | no round comparison | Series C · 2024-12-01 · $75M | no imminent plans |
| 40 | Mammoth Biosciences Brisbane, CA |
$1.0Bmark 2021-Q3 | $4.38as of 2026-06-27 | -67.4% | Series D · 2021-09-01 · $195M | no imminent plans |
| 41 | Xaira Therapeutics South San Francisco, CA |
$1.0Bmark 2024-Q2 | $4.39as of 2026-06-27 | no round comparison | Series A · 2024-04-23 · $1.0B | no imminent plans |
| 42 | Asimov Boston, MA |
$1.0Bmark 2026-02 | $82.00as of 2026-06-27 | -11.5% | Series B · 2026-02-01 · $175M | private |
| 43 | Truveta Bellevue, WA |
$1.0Bmark 2025-Q1 | no secondary mark | — | Series C · 2025-01-13 · $320M | private |
| 44 | Midi Palo Alto, CA |
$1.0Bmark 2026-Q1 | $2.37as of 2026-06-27 | -76.4% | Series D · 2026-02-02 · $100M | private |
| 45 | Alloy Therapeutics Waltham, MA |
$1.0Bmark 2026-Q2 | no secondary mark | — | Series E · 2026-04-15 · $40M | private |
| 46 | Axtria Berkeley Heights, NJ |
$1.0Bmark 2021-Q2 | no secondary mark | — | Series E · 2021-04-30 · $150M | private |
| 47 | Nutcracker Therapeutics Emeryville, CA |
$967Mmark 2022-Q1 | no secondary mark | — | Series C · 2022-03-14 · $167M | private |
| 48 | Immunai New York, NY |
$960Mmark 2021-Q4 | $127.25as of 2026-06-27 | -31.7% | Series C · 2021-12-01 · $204M | private |
| 49 | Target Healthcare Glasgow, United Kingdom |
$936Mmark 2022-Q2 | no secondary mark | — | Later Stage VC · 2022-04-08 · $164M | private |
| 50 | Domino Data Lab San Francisco, CA |
$916Mmark 2025-Q3 | $4.09as of 2026-06-27 | -75.1% | Series F · 2021-10-05 · $100M | private |
Methodology. Rankings are by each company's latest disclosed valuation (roster + weekly enrichment); the "mark" chip shows when that valuation was set. Secondary share prices are point estimates from secondary-market activity — one implied price per name, no bid/ask — refreshed daily (marks overlay as of 2026-08-16), each carrying its own date. "vs Last Round" compares the secondary price to the company's own last primary round per-share price; rows without a usable comparison say so rather than showing zero. Companies marked acquired, defunct, or public are excluded. Educational data, not investment advice.